WO2001036422A1 - Tricyclic dihydropyrimidine potassium channel openers - Google Patents
Tricyclic dihydropyrimidine potassium channel openers Download PDFInfo
- Publication number
- WO2001036422A1 WO2001036422A1 PCT/US2000/032333 US0032333W WO0136422A1 WO 2001036422 A1 WO2001036422 A1 WO 2001036422A1 US 0032333 W US0032333 W US 0032333W WO 0136422 A1 WO0136422 A1 WO 0136422A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrahydropyrazolo
- hydrogen
- compound according
- quinazolin
- aryl
- Prior art date
Links
- 0 C*C1C(C)=C(*C)*(C)(C)C2=CC=**12 Chemical compound C*C1C(C)=C(*C)*(C)(C)C2=CC=**12 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Definitions
- TECHNICAL FIELD Novel tricyclic dihydropyrimidine compounds and their derivatives can open potassium channels and are useful for treating a variety of medical conditions.
- Potassium channels play an important role in regulating cell membrane excitability. When the potassium channels open, changes in the electrical potential across the cell membrane occur and result in a more polarized state. A number of diseases or conditions may be treated with therapeutic agents that open potassium channels; for example, see K. Lawson, Pharmacol. Ther., v. 70, pp. 39-63 (1996); D.R. Gehlert et al., Prog. Neuro-Psychopharmacol & Biol. Psychiat., v. 18, pp. 1093-1 102 (1994); M. Gopalakrishnan et al., Drug Development Research, v. 28, pp. 95-127 (1993); J.E.
- Such diseases or conditions include asthma, hypertension, epilepsy, male sexual dysfunction, female sexual dysfunction, pain, bladder overactivity, stroke, diseases associated with decreased skeletal blood flow such as Raynaud's phenomenon and intermittent claudication, eating disorders, functional bowel disorders, neurodegeneration, benign prostatic hyperplasia (BPH), dysmenorrhea, premature labor, alopecia, cardioprotection, coronary artery disease, angina and ischemia.
- diseases or conditions include asthma, hypertension, epilepsy, male sexual dysfunction, female sexual dysfunction, pain, bladder overactivity, stroke, diseases associated with decreased skeletal blood flow such as Raynaud's phenomenon and intermittent claudication, eating disorders, functional bowel disorders, neurodegeneration, benign prostatic hyperplasia (BPH), dysmenorrhea, premature labor, alopecia, cardioprotection, coronary artery disease, angina and ischemia.
- Bladder overactivity is a condition associated with the spontaneous, uncontrolled contractions of the bladder smooth muscle. Bladder overactivity thus is associated with or can cause diseases and/or conditions such as sensations of urgency, urinary incontinence, pollakiuria, bladder instability, nocturia, bladder hyerreflexia, and enuresis (Resnick, The Lancet (1995) 346, 94-99; Hampel, Urology (1997) 50 (Suppl 6A), 4-14; Bosch, BJU International (1999) 83 (Suppl 2), 7-9). Potassium channel openers (KCOs) act as smooth muscle relaxants.
- KCOs Potassium channel openers
- bladder overactivity and urinary incontinence can result from the spontaneous, uncontrolled contractions of the smooth muscle of the bladder
- the ability of potassium channel openers to hyperpolarize bladder cells and relax bladder smooth muscle may provide a method to ameliorate or prevent bladder overactivity, pollakiuria, bladder instability, nocturia, bladder hyperreflexia, urinary incontinence, and enuresis (Andersson, Urology (1997) 50 (Suppl 6A), 74-84; Lawson, Pharmacol. Ther., (1996) 70, 39-63; Nurse., Br. J. Urol., (1991) 68, 27-31; Howe, J. Pharmacol. Exp. Ther., (1995) 274, 884-890; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).
- the excitability of corpus cavernosum smooth muscle cells is important in the male erectile process.
- the relaxation of corporal smooth muscle cells allows arterial blood to build up under pressure in the erectile tissue of the penis leading to erection (Andersson,
- Potassium channels play a significant role in modulating human corporal smooth muscle tone, and thus, erectile capacity.
- potassium channels have been characterized in human corporal smooth muscle cells (Lee, Int. J. Impot. Res. (1999) 11(4), 179- 188).
- Potassium channel openers are smooth muscle relaxants and have been shown to relax corpus cavernosal smooth muscle and induce erections (Andersson, Pharmacological Reviews (1993) 45, 253; Lawson, Pharmacol. Ther., (1996) 70, 39-63, Vick, J. Urol. (2000) 163: 202).
- Potassium channel openers therefore may have utility in the treatment of male sexual dysfunctions such as male erectile dysfunction, impotence and premature ejaculation.
- the sexual response in women is classified into four stages: excitement, plateau, orgasm and resolution.
- Sexual arousal and excitement increase blood flow to the genital area, and lubrication of the vagina as a result of plasma transudation.
- Topical application of KCOs like minoxidil and nicorandil have been shown to increase clitoral blood flow (J.J. Kim, J.W. Yu, J.G. Lee, D.G. Moon, "Effects of topical K-ATP channel opener solution on clitoral blood flow", J. Urol. (2000) 163 (4): 240).
- KCOs may be effective for the treatment of female sexual dysfunction including clitoral erectile insufficiency, vaginismus and vaginal engorgement (I. Goldstein and J.R. Berman., "Vasculogenic female sexual dysfunction: vaginal engorgement and clitoral erectile insufficiency syndromes"., Int. J. Impotence Res. (1998) 10:S84-S90), as KCOs can increase blood flow to female sexual organs.
- Potassium channel openers may have utility as tocolytic agents to inhibit uterine contractions to delay or prevent premature parturition in individuals or to slow or arrest delivery for brief periods to undertake other therapeutic measures (Sanborn, Semin. Perinatol. (1995) 19, 31-40; Morrison, Am. J. Obstet. Gynecol. (1993) 169(5), 1277-85). Potassium channel openers also inhibit contractile responses of human uterus and intrauterine vasculature. This combined effect would suggest the potential use of KCOs for dysmenhorrea (Kostrzewska, Acta Obstet. Gynecol. Scand. (1996) 75(10), 886-91). Potassium channel openers relax uterine smooth muscle and intrauterine vasculature and therefore may have utility in the treatment of premature labor and dysmenorrhoea (Lawson, Pharmacol. Ther., (1996) 70, 39-63).
- Potassium channel openers relax gastrointestinal smooth tissues and therefore may be useful in the treatment of functional bowel disorders such as irritable bowel syndrome (Lawson, Pharmacol. Ther., (1996) 70, 39-63).
- Potassium channel openers relax airways smooth muscle and induce bronchodilation. Therefore potassium channel openers may be useful in the treatment of asthma and airways hyperreactivity (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Buchheit, Pulmonary Pharmacology & Therapeutics (1999) 12, 103; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127). Neuronal hyperpolarization can produce analgesic effects. The opening of potassium channels by potassium channel openers and resultant hyperpolarization in the membrane of target neurons is a key mechanism in the effect of opioids.
- K A ⁇ p channels by potassium channel openers plays an important role in the antinociception mediated by alpha-2 adrenoceptors and mu opioid receptors.
- KCOs can potentiate the analgesic action of both morphine and dexmedetomidine via an activation of K ATP channels at the spinal cord level (Vergoni, Life Sci. (1992) 50(16), PL135-8; Asano, Anesth. Analg.
- potassium channel openers can hyperpolarize neuronal cells and have shown analgesic effects. Potassium channel openers therefore may be useful as analgesics in the treatment of various pain states including but not limited to migraine and dyspareunia (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog. Neuro-Psychopharmacol. & Biol. Psychia , (1994) 18, 1093-1102).
- Epilepsy results from the propagation of rionphysiologic electrical impulses. Potassium channel openers hyperpolarize neuronal cells and lead to a decrease in cellular excitability and have demonstrated antiepileptic effects. Therefore potassium channel openers may be useful in the treatment of epilepsy (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog. Neuro- Psychopharmacol. & Biol. Psychiat., (1994) 18, 1093-1102).
- Potassium channel openers can hyperpolarize neuronal cells and lead to a decrease in cellular excitability. Activation of potassium channels has been shown to enhance neuronal survival. Therefore potassium channel openers may have utility as neuroprotectants in the treatment of neurodegenerative conditions and diseases such as cerebral ischemia, stroke, Alzheimer's disease and Parkinson's disease (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog.
- Potassium channel openers may have utility in the treatment of diseases or conditions associated with decreased skeletal muscle blood flow such as Raynaud's syndrome and intermittent claudication (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Dompeling Vasa. Supplementum (1992) 3434; and WO9932495). Potassium channel openers may be useful in the treatment of eating disorders such as obesity (Spanswick, Nature, (1997) 390, 521-25; Freedman, The Neuroscientist (1996) 2, 145).
- Potassium channel openers have been shown to promote hair growth therefore potassium channel openers have utility in the treatment of hair loss and baldness also known as alopecia (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).
- Potassium channel openers possess cardioprotective effects against myocardial injury during ischemia and reperfusion. (Garlid, Circ. Res. (1997) 81(6), 1072-82). Therefore, potassium channel openers may be useful in the treatment of heart diseases (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Grover, J. Mol. Cell Cardiol. (2000) 32, 677).
- Potassium channel openers by hyperpolarization of smooth muscle membranes, can exert vasodilation of the collateral circulation of the coronary vasculature leading to increase blood flow to ischemic areas and could be useful for the coronary artery disease (Lawson, Pharmacol. Ther., (1996) 70, 39-63, Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).
- n is an integer of 0- 1 ;
- m is an integer of 1-2; provided that when m is 2, n is 0;
- R 1 is selected from aryl and heterocycle
- Q is selected from C(O), S(O), and S(O) 2 ;
- V is selected from C(R )(R ), O, S, and NR , wherein R is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are independently selected from hydrogen and lower alkyl; R 6 and R 7 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl
- X is selected from N and CR wherein R is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above; and
- D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above.
- R 1 is selected from aryl and heterocycle;
- Q is selected from C(O), S(O), and S(O) 2 ;
- V is selected from C(R 6 )(R 7 ), O, S, and NR 2 , wherein R 2 is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are independently selected from hydrogen and lower alkyl;
- R 6 and R 7 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above;
- R 8 and R 9 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above;
- X is selected from N and CR wherein R is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above; and
- D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR R , and (NR R )alkyl wherein R and R are as defined above.
- compounds have formula (I) wherein, R is aryl; X is CR ; R is hydrogen; and R , R , D, E, Q, V, m, and n are as defined in formula (I).
- compounds have formula (I) wherein, R 1 is heterocycle; X is CR 3 ; R 3 is hydrogen; and R 8 , R 9 , D, E, Q, V, m, and n are as defined in formula (I).
- compounds of the present invention have formula (II):
- R 1 is selected from aryl and heterocycle;
- Q is selected from C(O), S(O), and S(O) 2 ;
- V is selected from C(R 6 )(R 7 ), O, S, and NR 2 , wherein R 2 is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are independently selected from hydrogen and lower alkyl; are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl,
- R 8 and R 9 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above; and
- D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above.
- compounds have formula (II) wherein, R 1 is heterocycle; Q is C(O); and R 8 , R 9 , D, E, and V are as defined in formula
- compounds have formula (II) wherein, R 1 is heterocycle; Q is S(O); and R 8 , R 9 , D, E, and V are as defined in formula
- R 1 is heterocycle
- Q is S(O)
- R 8 , R 9 , D, E, and V are as defined in formula
- compounds have formula (II) wherein, R 1 is heterocycle; Q is C(O); V is S; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is heterocycle; Q is C(O); V is S; and R 8 , R 9 , D, and E are hydrogen.
- compounds have formula (II) wherein, R 1 is heterocycle; Q is C(O); V is CH 2 ; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is heterocycle; Q is S(O) ; V is CH 2 ; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is heterocycle; Q is S(O) 2 ; V is CH 2 ; and R 8 , R 9 , D, and E are hydrogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); and R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is S; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is S; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is S; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is S; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is S; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (
- R 1 is aryl; Q is C(O); V is S; and R 8 , R 9 , D, and E are hydrogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; and R 8 , R 9 , D, and E are as defined in formula
- R 1 is aryl; Q is C(O); V is CH 2 ; D is alkyl; E is alkyl; and R 8 and R 9 are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; D is alkyl; E is alkyl; and R 8 and R 9 are hydrogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is aryl; and R 8 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is aryl; and R 8 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is aryl; and R 8 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is aryl; and R 8 , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is ary
- R is aryl; Q is C(O); V is CH ; R is aryl; and R , D, and E are hydogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is heterocycle; and R 8 , D, and E are as defined in formula (I).
- R is aryl; Q is C(O); V is CH 2 ; R is halogen; and R , D, and E are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; R 9 is halogen; and R 8 , D, and E are hydogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; and R 8 , R 9 , D, and E are hydrogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; and R 8 , R 9 , D, and E are hydrogen.
- compounds have formula (II) wherein, R 1 is aryl; Q is C(O); V is CH 2 ; and R 8 , R 9 , D, and E are hydrogen.
- R 1 is aryl; Q is S(O); and R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is S(O) 2 ; and R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds have formula (II) wherein, R 1 is aryl; Q is S(O) 2 ; V is CH 2 ; and R 8 , R 9 , D, and E are as defined in formula
- compounds have formula (II) wherein, R 1 is aryl; Q is S(O) 2 ; V is CH 2 ; and R 8 , R 9 , D, and E are hydrogen.
- compounds of the present invention have formula (III):
- R 1 is selected from aryl and heterocycle
- Q is selected from C(O), S(O), and S(O) 2
- V is selected from C(R 6 )(R 7 ), O, S, and NR 2
- R 2 is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are independently selected from hydrogen and lower alkyl; R and R are independently selected from hydrogen, alkenyl, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, ary
- R is heterocycle
- Q is S(O) 2
- R , R , D, E, and V are as defined in formula
- R is aryl; Q is C(O); and R , R , D, E, and V are as defined in formula (I).
- compounds have formula (III) wherein, R 1 is aryl; Q is C(O); V is O; and R 8 , R 9 , D, and E are as defined in formula (I).
- compounds have formula (III) wherein, R 1 is aryl; Q is C(O); V is O; and R 8 , R 9 , D, and E are hydrogen.
- compounds have formula (III) wherein, R 1 is aryl; Q is S(O); and R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds have formula (III) wherein, R 1 is aryl; Q is S(O); and R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds have formula (III) wherein, R 1 is aryl; Q is S(O); and R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds have formula (III) wherein, R 1 is aryl; Q is S(O); and R 8 , R 9 , D, E, and V are as defined in formula (I).
- R 1 is aryl
- Q is S(O) 2
- R 8 , R 9 , D, E, and V are as defined in formula (I).
- compounds of the present invention have formula (IV):
- R 1 is selected from aryl and heterocycle
- Q is selected from C(O), S(O), and S(O) 2
- V is selected from C(R 6 )(R 7 ), O, S, and NR 2 , wherein R 2 is selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are independently selected from hydrogen and lower alkyl;
- R 6 and R 7 are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above;
- R and R are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above; and
- D and E are independently selected from hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkyl, alkylthio, alkynyl, aryl, arylalkoxy, arylalkenyl, arylalkyl, carboxy, cyano, cycloalkyl, cycloalkylalkyl, haloalkoxy, haloalkyl, halogen, heterocycle, heterocyclealkyl, hydroxy, hydroxyalkyl, oxo, -NR 4 R 5 , and (NR 4 R 5 )alkyl wherein R 4 and R 5 are as defined above.
- compounds have formula (IV) wherein, R 1 is heterocycle; Q is C(O); R 8 , R 9 , D, and E are as defined in formula (I); and V is as defined in formula (IV).
- R is heterocycle
- Q is S(O)
- R , R , D, and E are as defined in formula (I);
- V is as defined in formula (IV).
- compounds have formula (IV) wherein, R is heterocycle; Q is S(O) 2 ; R , R , D, and E are as defined in formula (I); and
- V is as defined in formula (IV).
- compounds have formula (IV) wherein, R is aryl; Q is S(O) 2 ; R , R , D, and E are as defined in formula (I); and V is as defined in formula (IV).
- compositions comprising a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
- Another embodiment of the invention relates to a method of treating male sexual dysfunction including, but not limited to, male erectile dysfunction and premature ejaculation, comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- Another embodiment of the invention relates to a method of treating female sexual dysfunction including, but not limited to, female anorgasmia, clitoral erectile insufficiency, vaginal engorgement, dyspareunia, and vaginismus comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- Yet another embodiment of the invention relates to a method of treating asthma, epilepsy, Raynaud's syndrome, intermittent claudication, migraine, pain, bladder overactivity, pollakiuria, bladder instability, nocturia, bladder hyperreflexia, eating disorders, urinary incontinence, enuresis, functional bowel disorders, neurodegeneration, benign prostatic hype ⁇ lasia (BPH), dysmenorrhea, premature labor, alopecia, cardioprotection, and ischemia comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- BPH benign prostatic hype ⁇ lasia
- dysmenorrhea premature labor
- alopecia cardioprotection
- ischemia comprising administering a therapeutically effective amount of a compound of formula (I-IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
- alkenyl refers to a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
- Representative examples of “alkenyl” include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5- hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, 3-decenyl and the like.
- alkenyloxy refers to an alkenyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- alkenyloxy include, but are not limited to, propen-3-yloxy (allyloxy), buten-4-yloxy, and the like.
- alkoxy refers to an alkyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, hexyloxy and the like.
- alkoxyalkoxy refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through another alkoxy group, as defined herein.
- Representative examples of alkoxyalkoxy include, but are not limited to, tert-butoxymethoxy, 2-ethoxyethoxy, 2-methoxyethoxy, methoxymethoxy, and the like.
- alkoxyalkyl refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of alkoxyalkyl include, but are not limited to, tert-butoxymethyl, 2- ethoxyethyl, 2-methoxyethyl, methoxymethyl, and the like.
- alkoxycarbonyl refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- alkoxycarbonyl examples include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, tert-butoxycarbonyl, and the like.
- alkyl refers to a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
- alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, n-decyl, and the like.
- alkylcarbonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1 -oxopropyl, 2,2-dimethyl-l -oxopropyl, 1-oxobutyl, 1 -oxopentyl, and the like.
- alkylcarbonyloxy refers to an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, tert-butylcarbonyloxy, and the like.
- alkylsulfinyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein.
- Representative examples of alkylsulfinyl include, but are not limited, methylsulfinyl, ethylsulfinyl, and the like.
- alkylsulfonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
- Representative examples of alkylsulfonyl include, but are not limited, methylsulfonyl, ethylsulfonyl, and the like.
- alkylthio refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a thio moiety, as defined herein.
- Representative examples of alkylthio include, but are not limited, methylthio, ethylthio, tert- butylthio, hexylthio, and the like.
- alkynyl refers to a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. Representative examples of alkynyl include, but are not limited, to acetylenyl, 1 - propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, 1-butynyl and the like.
- aryl refers to a monocyclic carbocyclic ring system or a bicyclic carbocyclic fused ring system having one or more aromatic rings.
- aryl include, azulenyl, indanyl, indenyl, naphthyl, phenyl, tetrahydronaphthyl, and the like.
- the aryl groups of this invention can be substituted with 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, aryl, aryloxy, azido, arylalkoxy, arylalkyl, aryloxy, carboxy, cyano, formyl, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, mercapto, nitro, sulfamyl, sulfo, sulf
- arylalkoxy refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- arylalkoxy include, but are not limited to, 2-phenylethoxy, 3- naphth-2-ylpropoxy, 5-phenylpentyloxy, and the like.
- arylalkoxycarbonyl refers to an arylalkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
- Representative examples of arylalkoxy include, but are not limited to, benzyloxycarbonyl, naphth-2-ylmethoxycarbonyl, and the like.
- arylalkyl refers to an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- arylalkyl include, but are not limited to, benzyl, 2-phenylethyl, 3- phenylpropyl, 2-naphth-2-ylethyl, and the like.
- aryloxy refers to an aryl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
- Representative examples of aryloxy include, but are not limited to, phenoxy, naphthyloxy, and the like.
- zido refers to an -N 3 group.
- carbonyl refers to a -C(O)- group.
- carboxy refers to a -CO 2 H group.
- carboxy protecting group refers to a carboxylic acid protecting ester group employed to block or protect the carboxylic acid functionality while the reactions involving other functional sites of the compound are carried out. Carboxy- protecting groups are disclosed in T.H. Greene and P.G.M. Wuts, Protective Groups in Organic Synthesis, 2nd edition, John Wiley & Sons, New York (1991), which is hereby inco ⁇ orated herein by reference.
- a carboxy-protecting group can be used as a prodrug whereby the carboxy-protecting group can be readily cleaved in vivo, for example by enzymatic hydrolysis, to release the biologically active parent.
- T. Higuchi and V. Stella provide a thorough discussion of the prodrug concept in "Pro-drugs as Novel Delivery Systems", Vol 14 of the A.C.S. Symposium Series, American Chemical Society (1975), which is hereby inco ⁇ orated herein by reference.
- Such carboxy-protecting groups are well known to those skilled in the art, having been extensively used in the protection of carboxyl groups in the penicillin and cephalosporin fields, as described in U.S. Pat. No.
- esters useful as prodrugs for compounds containing carboxyl groups can be found on pages 14-21 of "Bioreversible Carriers in Drug Design: Theory and Application", edited by E.B. Roche, Pergamon Press, New York (1987), which is hereby inco ⁇ orated herein by reference.
- Representative carboxy-protecting groups are loweralkyl (e.g., methyl, ethyl or tertiary butyl and the like); benzyl (phenylmethyl) and substituted benzyl derivatives thereof such substituents are selected from alkoxy, alkyl, halogen, and nitro groups and the like.
- cyano refers to a -CN group.
- cycloalkyl refers to a saturated cyclic hydrocarbon group containing from 3 to 8 carbons. Representative examples of cycloalkyl include, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
- cycloalkylalkyl refers to cycloalkyl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of cycloalkylalkyl include, but are not limited to, cyclopropylmethyl, 2-cyclobutylethyl, cyclopentylmethyl, cyclohexylmethyl and 4-cycloheptylbutyl, and the like.
- haloalkyl refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifluoromethyl, pentafluoroethyl, 2-chloro-3-fluoropentyl, and the like.
- haloalkoxy refers to at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
- haloalkoxy include, but are not limited to, 2-chloroethoxy, difluoromethoxy, 1 ,2-difluoroethoxy, 2,2,2-trifluoroethoxy, trifluoromethoxy, and the like.
- heterocycle refers to a monocyclic- or a bicyclic-ring system.
- Monocyclic ring systems are exemplified by any 5 or 6 membered ring containing 1, 2, 3, or 4 heteroatoms independently selected from oxygen, nitrogen and sulfur.
- the 5 membered ring has from 0-2 double bonds and the 6 membered ring has from 0-3 double bonds.
- monocyclic ring systems include, but are not limited to, azetidine, azepine, aziridine, diazepine, 1,3-dioxolane, dioxane, dithiane, furan, imidazole, imidazoline, imidazolidine, isothiazole, isothiazoline, isothiazolidine, isoxazole, isoxazoline, isoxazolidine, mo ⁇ holine, oxadiazole, oxadiazoline, oxadiazolidine, oxazole, oxazoline, oxazolidine, piperazine, piperidine, pyran, pyrazine, pyrazole, pyrazoline, pyrazolidine, pyridine, pyrimidine, pyridazine, pyrrole, pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, tetrazine,
- Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to an aryl group as defined herein, a cycloalkyl group as defined herein, or another monocyclic ring system as defined herein.
- Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazole, benzothiazole, benzothiadiazole, benzothiophene, benzoxadiazole, benzoxazole, benzofuran, benzopyran, benzothiopyran, benzodioxine, 1,3-benzodioxole, cinnoline, indazole, indole, indoline, indolizine, naphthyridine, isobenzofuran, isobenzothiophene, isoindole, isoindoline, isoquinoline, phthalazine, pyranopyridine, quinoline, quinolizine, qui
- heterocycle groups of this invention can be substituted with 1, 2,or 3 substituents independently selected from alkenyl, alkenyloxy, alkoxy, alkoxyalkoxy, alkoxycarbonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, aryl, azido, arylalkoxy, arylalkoxycarbonyl, arylalkyl, aryloxy, carboxy, cyano, formyl, halogen, haloalkyl, haloalkoxy, hydroxy, hydroxyalkyl, mercapto, nitro, sulfamyl, sulfo, sulfonate, - NR R (wherein, R and R are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl and formyl), and -C(
- heterocyclealkyl refers to a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- heterocyclealkyl include, but are not limited to, pyrid-3-ylmethyl, 2-pyrimidin-2-ylpropyl, and the like.
- hydroxy refers to an -OH group.
- hydroxyalkyl refers to a hydroxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxy ethyl, 3-hydroxypropyl, and the like.
- lower alkyl is a subset of alkyl as defined herein and refers to a straight or branched chain hydrocarbon group containing from 1 to 4 carbon atoms.
- Representative examples of lower alkyl include, but are not limited to, methyl, ethyl, n- propyl, iso-propyl, n-butyl, iso-butyl, tert-butyl, and the like.
- mercapto refers to a -SH group.
- (NR 4 R 5 )alkyl refers to a -NR 4 R 5 group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
- Representative examples of (NR 4 R 5 )alkyl include, but are not limited to, aminomethyl, dimethylaminomethyl, 2-(amino)ethyl, 2-(dimethylamino)ethyl, and the like.
- nitro refers to a -NO 2 group.
- oxy refers to a -O- moiety.
- sulfamyl refers to a -SO 2 NR 94 R 95 group, wherein, R 94 and R 95 are independently selected from hydrogen, alkyl, aryl, and arylalkyl, as defined herein.
- sulfinyl refers to a -S(O)- group.
- sulfo refers to a -SO 3 H group.
- sulfonate refers to a -S(O) 2 OR 96 group, wherein, R 96 is selected from alkyl, aryl, and arylalkyl, as defined herein.
- sulfonyl refers to a -SO 2 - group.
- thio refers to a -S- moiety.
- Preferred compounds of formula (I) include, but are not limited to: 9-(3-bromo-4-fluorophenyl)-5,6,7,9-tetrahydropyrazolo[5, 1 -b]quinazolin-8(4H)-one;
- the compounds of this invention can be prepared by a variety of synthetic routes. Representative procedures are shown in Schemes 1-20.
- Fused pyrimidines of general formula (4) wherein R 1 , X, Q, R 8 , R 9 , D and E are as defined in formula (I) and m is an integer 1-2, can be prepared according to the method of Scheme 1.
- a carbonyl component of general formula (1) can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (4).
- Fused pyrimidines of general formula (6) wherein R , X, Q, V, R , R , D, and E are as defined in formula (I), can be prepared according to the method of Scheme 2.
- a carbonyl component of general formula (5) can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (6).
- Carbonyl components of general formula (5) may be prepared using the procedures described in (Dodd, J.H., Journal of Heterocyclic Chemistry 27 (1990) 1453; Terasawa, T., Journal of Organic Chemistry 42 (1977) 1163).
- Fused pyrimidines of general formula (8) wherein R 1 , X, Q, V, R 8 , R 9 , D, and E are as defined in formula (I), can be prepared according to the method of Scheme 3.
- a carbonyl component of general formula (7) can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (8).
- Carbonyl components of general formula (7) may be prepared as described in (Nakagawa, S., Heterocycles 13 (1979) 477; D'Angelo, J., Tetrahedron Letters 32 (1991) 3063).
- Fused pyrimidines of general formula (10), wherein R , X, Q, V, R , R , D, and E are as defined in formula (I), can be prepared according to the method of Scheme 4.
- a carbonyl component of general formula (9) can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (10).
- Fused pyrimidines of general formula (13), wherein R 1 , X, R 8 , R 9 , and D are as defined in formula (I), can be prepared according to the method of Scheme 5.
- a dicarbonyl component of general formula (1 1), wherein R' is selected from Cl and OAc and R is selected from lower alkyl, cyanoalkyl, and carboxy protecting group, can be treated with an aldehyde of general formula (2) and an amino heterocycle of general formula (3) in a solvent such as ethanol, acetonitrile or dimethylformamide with heating to provide fused pyrimidines of general formula (12).
- R' is OAc
- cleavage of the acetyl group may be required to induce cyclization to provide fused pyrimidines of general formula (13).
- R' is Cl
- cyclization can proceed directly without the isolation of (12) to provide fused pyrimidines of general formula (13).
- a para substituted aldehyde of general formula (20) or the corresponding acetal protected aldehyde of general formula (22), wherein R is selected from alkyl or together with the oxygen atoms to which they are attached form a 5 or 6 membered ring wherein 1,3-dioxolanes are preferred, may by subjected to conditions of an electrophilic aromatic substitution reaction to provide aldehydes of general formula (21) or protected aldehydes of general formula (23).
- Preferred protecting groups for compounds of general formula (22) and (23) include dimethyl or diethyl acetals or the 1,3-dioxolanes. These protecting groups can be introduced at the beginning and removed at the end to provide substituted aldehydes of general formula (21) using methods well known to those skilled in the art of organic chemistry.
- a meta substituted phenol (25) is converted to the para substituted salicylaldehyde (26) by reaction with a base such as sodium hydroxide and a reagent such as trichloromethane or tribromomethane, known as the Reimer-Tiemann reaction.
- a base such as sodium hydroxide
- a reagent such as trichloromethane or tribromomethane, known as the Reimer-Tiemann reaction.
- An alternate set of reaction conditions involves reaction with magnesium methoxide and paraformaldehyde (Aldred, J. Chem. Soc. Perkin Trans. 1 (1994), 1823).
- the aldehyde (26) may be subjected to conditions of an electrophilic aromatic substitution reaction to provide meta, para disubstituted salicylaldehydes of general formula (27).
- a meta, para disubstituted phenol of general formula (28) can be reacted with a base such as sodium hydroxide and a reagent such as trichloromethane or tribromomethane, known as the Reimer-Tiemann reaction, to provide disubstituted salicylaldehydes of general formula (27).
- a base such as sodium hydroxide
- a reagent such as trichloromethane or tribromomethane, known as the Reimer-Tiemann reaction
- An alternate set of reaction conditions involves reaction with magnesium methoxide and paraformaldehyde (Aldred, J. Chem. Soc. Perkin Trans. 1 (1994), 1823).
- R is selected from alkyl, haloalkyl, chlorine, fluorine, haloalkoxy, alkoxy, alkylthio, nitro, alkylcarbonyl, arylcarbonyl, -NR 82 R 83 , and -C(O)NR 82 R 83 wherein R 82 and R 83 are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, and R is selected from alkyl, hydroxyalkyl, alkylthio, alkylcarbonyl, and formyl, is described in Scheme 9.
- Protected benzaldehydes of general formula (29), wherein R is selected from alkyl or together with the oxygen atoms to which they are attached form a 5 or 6 membered ring wherein 1,3 -dioxolanes are preferred, can be converted to the 3,4-disubstituted benzaldehyde of general formula (23) via conversion of the bromide to an intermediate lithio or magnesio derivative, followed by reaction with an appropriate electrophile such as an aldehyde, dialkyldisulfide, a Weinreb amide, dimethylformamide, an alkyl halide or other electrophile followed by deprotection of the acetal to provide benzaldehydes of general formula (21).
- an appropriate electrophile such as an aldehyde, dialkyldisulfide, a Weinreb amide, dimethylformamide, an alkyl halide or other electrophile followed by deprotection of the acetal to provide
- R 82 and R 83 are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl
- R 12 is selected from alkyl, hydroxyalkyl.
- alkylthio, alkylcarbonyl, arylcarbonyl, and formyl can be used as described in Scheme 10.
- 3- Hydroxybenzaldehyde of general formula (32) can be treated with suitable alkylating reagents such as benzylbromide, iodomethane, 2-iodo- 1,1,1 -trifluoroethane, chlorodifluoromethane, or dibromodifluoromethane in the presence of base such as potassium carbonate, potassium tert- butoxide or sodium tert-butoxide, to provide benzaldehydes of general formula (33).
- base such as potassium carbonate, potassium tert- butoxide or sodium tert-butoxide
- 4- Hydroxybenzaldehydes of general formula (34) can be treated with suitable alkylating reagents such as benzylbromide, iodomethane, 2-iodo- 1,1,1 -trifluoroethane, chlorodifluoromethane, or dibromodifiuoromethane, in the presence of base such as potassium carbonate, potassium tert-butoxide or sodium tert-butoxide to provide benzaldehydes of general formula (35).
- suitable alkylating reagents such as benzylbromide, iodomethane, 2-iodo- 1,1,1 -trifluoroethane, chlorodifluoromethane, or dibromodifiuoromethane
- base such as potassium carbonate, potassium tert-butoxide or sodium tert-butoxide
- This method also known as the Sandmeyer reaction, involves converting 3-amino benzaldehydes of general formula (36) to an intermediate diazonium salt with sodium nitrite.
- the diazonium salts can be treated with a bromine or iodine source to provide the bromide or iodide.
- the Sandmeyer reaction and conditions for effecting the transformation are well known to those skilled in the art of organic chemistry.
- the types of R substituents that may be introduced in this fashion include cyano, hydroxy, or halo. In order to successfully carry out this transformation it may in certain circumstances be advantageous to perform the Sandmeyer reaction on a protected aldehyde.
- the resulting iodide or bromide can be treated with imsaturated halides, boronic acids or tin reagents in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) to provide benzaldehydes of general formula (21).
- a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0)
- the diazonium salts may also be treated directly with unsaturated halides, boronic acids or tin reagents in the presence of a palladium catalyst such as tetrakis(triphenylphosphine)palladium (0) to provide benzaldehydes of general formula (21).
- This method also known as the Sandmeyer reaction, involves converting 4-amino benzaldehydes of general formula (37) to an intermediate diazonium salt with sodium nitrite and then treating the diazonium salts in a similar manner as that described in Scheme 13.
- the types of R 10 substituents that may be introduced in this fashion include cyano, hydroxy, or halo.
- the Sandmeyer reaction and conditions for effecting the transformation are well known to those skilled in the art of organic chemistry. In order to successfully carry out this transformation it may in certain circumstances be advantageous to perform the Sandmeyer reaction on a protected aldehyde.
- 4-Bromo-3-(trifluoromethoxy)benzaldehyde or 4-chloro-3- (trifluoromethoxy)benzaldehyde can be prepared as described in Scheme 15.
- the commercially available 4-bromo-2-(trifluoromethoxy)aniline can be protected on the amino group with a suitable N-protecting group well known to those skilled in the art of organic chemistry such as acetyl or tert-butoxycarbonyl.
- the bromine can then be converted to the lithio or magnesio derivative and reacted directly with dimethylformamide to provide the 4- aminoprotected-3-(trifluoromethoxy)benzaldehyde derivative.
- Trifiuoromethylbenzoic acid is first nitrated, using suitable conditions well known in the literature such as nitric acid with sulfuric acid, and the carboxylic acid group reduced with borane to provide 3-nitro-4-trifluoromethylbenzyl alcohol. From this benzyl alcohol may be obtained the 3-nitro-4-trifluoromethylbenzaldehyde by oxidation with typical reagents such as manganese dioxide.
- the nitro benzylic alcohol can be reduced to the aniline using any of a number of different conditions for effecting this transformation among which a preferred method is hydrogenation over a palladium catalyst.
- the aniline can be converted to either a halo or cyano substituent using the Sandmeyer reaction described in Scheme 13.
- Benzyl alcohols of general formula (38) can be oxidized using conditions well known to those skilled in the art such as manganese dioxide or swern conditions to provide benzaldehydes of general formula (39).
- haloalkoxy, and arylalkoxy, R is selected from alkyl, vinyl, aryl, heteroaryl, cyano and the like, can be prepared as described in Scheme 17.
- Compounds of general formula (41), wherein Y is selected from bromine, iodine, and triflate, are protected with a tert- butoxycarbonyl (Boc) group using standard procedures.
- the aromatic bromide, iodide, or triflate can be treated with a suitable tin, boronic acid, or unsaturated halide reagent in the presence of a palladium catalyst with heating in a solvent such as dimethylformamide to effect a coupling reaction that provides dihydropyridines of general formula (42).
- the conditions for this transformation also effect the removal of the Boc protecting group.
- R is selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, chlorine, fluorine, haloalkoxy, nitro, alkoxy, alkylthio, and - x9 R ⁇ R9 R ⁇
- R and R are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl
- R 11 is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy
- R 10 is selected from alkyl, vinyl, aryl, heteroaryl, cyano and the like, can be prepared as described in Scheme 18.
- Dihydropyridines of general formula (43), wherein Y is selected from bromine, iodine, and triflate, can be protected with a tert- butoxycarbonyl (Boc) group using standard procedures.
- R and R are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, and R 11 is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy, can be prepared as described in Scheme 19.
- Dihydropyridines of general formula (41), wherein Y is selected from bromine, iodine, and triflate can be protected with a tert-butoxycarbonyl (Boc) group using standard procedures.
- Dihydropyridines of general formula (48), R , R , D, E, Q, V, X, m, and n are as defined in formula (I)
- R 10 is selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, heteroaryl, cyano, haloalkyl, chlorine, fluorine, haloalkoxy, nitro, alkoxy, alkylthio, - C(O)NR 82 R 83 wherein R 82 and R 83 are independently selected from hydrogen, alkyl, alkylcarbonyl, aryl, arylalkyl, and formyl, R 1 ' is selected from hydrogen, hydroxy, alkoxy, haloalkoxy, and arylalkoxy, can be prepared as described in Scheme 20.
- Dihydropyridines of general formula (43), wherein Y is selected from bromine, iodine, and triflate can be protected with a tert-butoxycarbonyl (Boc) group using standard procedures.
- the aromatic bromide, iodide, or triflate can be treated with a suitable halozinc reagent in the presence of a palladium catalyst with heating in a solvent such as dimethylformamide to effect a coupling reaction that provides dihydropyridines of general formula (48).
- the conditions for this transformation also effect the removal of the Boc protecting group.
- the types of para substituents that may be introduced in this fashion include trihalopropenyl and more specifically the trifluoropropenyl group.
- Fused pyrimidines of general formula (52), wherein R 1 , X, Q, V, R 8 , D, E, m and n are as defined in formula (I) and R 9 is selected from alkenyl, alkynyl, aryl and heterocycle, can be prepared according to the method of Scheme 21.
- Fused pyrimidines of general formula (50) may be treated with N-bromosuccinimide (NBS) in a solvent such as methylene chloride to provide bromides of general formula (51).
- Bromides of general formula (51) may be treated with a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium (0), an organoborane reagent and a base such as cesium fluoride or potassium carbonate under Suzuki conditions which are known to those of skill in the art (Syn. Comm. 11, 1981, 513; JOC 49, 1984, 5237; Tet. Lett. 26, 1985, 5997; Tet. Lett. 28, 1987, 5093; and Tet. Lett. 28, 1987, 5097) to provide fused pyrimidines of general formula (52).
- a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium (0)
- an organoborane reagent such as cesium fluoride or potassium carbonate
- Bromides of general formula (51) may also be treated with a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium (0) and a tin reagent under Stille conditions which are known to those of skill in the art (JACS 101, 1979, 4992) to provide fused pyrimidines of general formula (52).
- Bromides of general formula (51) may also be treated with a palladium (0) catalyst, an aryl halide (Br or I) or a heterocyclic halide (Br or I) and a base such as triethylamine under biaryl coupling conditions or Heck conditions which are known to those of skill in the art to provide fused pyrimidines of general formula (52).
- a palladium (0) catalyst such as tetrakis(triphenylphosphine)palladium (0) and a tin reagent under Stille conditions which are known to those of skill in the art (JACS 101, 1979, 4992
- Example 1 9-(4-bromo-3-fluorophenyl)-5.6.7.9-tetrahvdropyrazolo 5,l-b]quinazolin-8(4H)-one
- 1,3-cyclohexanedione (0.56 g, 5 mmol)
- 3-bromo-4-fluorobenzaldehyde (1.01 g, 5 mmol)
- 3-aminopyrazole 0.41 g, 5 mmol
- Example 3 9-(l-naphthyl)-5.6.7.9-tetrahvdropyrazolor5,l-b]quinazolin-8(4H)-one
- 1,3-cyclohexanedione (0.11 g, 1 mmol)
- 1-naphthaldehyde (0.16 g, 1 mmol)
- 3-aminopyrazole (0.11 g, 1.27 mmol) in ethanol (10 mL) were heated at 80 °C in a sealed 20 mL vial for 3 days.
- Example 4 9-f2-naphthylV5.6 ,9-tetrahvdropyrazolo[5,l-b1quinazolin-8(4H)-one 2-Naphthaldehyde (0.16 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.16 g (51%) of the title compound.
- Example 5 9-(3.4-dibromophenylV5.6.7,9-tetrahvdropyrazolor5,l-blquinazolin-8(4H)-one
- 1,3-cyclohexanedione 0.1 1 g, 1 mmol
- 3,4-dibromobenzaldehyde 0.1 1 g, 1 mmol
- 3-aminopyrazole 0.11 g, 1.27 mmol
- Example 7 9-(3-bromophenyl)-5.6.7.9-tetrahvdropyrazolor5.1-b]quinazolin-8( ' 4H)-one 3-Bromobenzaldehyde (0.19 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.21 g (60%) of the title compound.
- Example 8 9-(3-chlorophenyl)-5,6,7,9-tetrahvdropyrazolof5,l-b]quinazolin-8f4H ' )-one 3-Chlorobenzaldehyde (0.14 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (49%) of the title compound.
- Example 11 9-r3-(trifluoromethoxy)pheny ⁇ -5,6,7.9-tetrahvdropyrazolo[5.1-b]quinazolin-8(4H)-one 3-Trifluoromethoxybenzaldehyde (0.19 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (50%) of the title compound.
- Example 12 9-(3 -cvanophenyl)-5 ,6.7,9-tetrahydropyrazolo [5.1 -blq uinazolin-8(4H)-one 3-Cyanobenzaldehyde (0.13 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.16 g (55%) of the title compound.
- Example 13 9-(3-methylphenyl)-5.6.7.9-tetrahvdropyrazolo[ " 5.1-b1quinazolin-8(4H)-one 3-Methylbenzaldehyde (0.12 g, 1 mmol) was treated according to the procedure described in Example 3 to provide 0.17 g (60%) of the title compound.
- Example 14 8-( " 3-bromo-4-fluorophenyl)-5,8-dihvdro-4H.7H-furo[3.4-d pyrazolori,5-a]pyrimidin-7-one
- Example 17 9-(3-bromo-4-fluorophenyl)-5.6,7.9-tetrahvdro-4H-pyrazolo
- a solution of tetrahydrothiopyran-3 -one- 1,1 -dioxide (0.74 g, 5 mmol), 3-bromo-4- fluorobenzaldehyde (1.01 g, 5 mmol), and 3-aminopyrazole (0.41 g, 5 mmol) in ethanol (5 mL) was heated at reflux for 24 hours. After the reaction mixture was allowed to cool to ambient temperature, the solid that precipitated was filtered off, washed with ethanol, and dried to provide the title compound.
- Example 18 9-( " 3-chloro-4-hydroxyphenyl)-5,6,7.9-tetrahvdropyrazolo[5,l-b1quinazolin-8(4H)-one 1,3-Cyclohexanedione, 3-chloro-4-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 19 3-bromo-9-(3-bromo-4-fluorophenyl)-5.6.7.9-tetrahydropyrazolor5.1-b1quinazolin-8(4HVone
- the product from Example 1 and N-bromosuccinimide were processed as described in Example 48 to provide the title compound.
- Example 20 9- 3-chloro-4-fluorophenv ⁇ -5.6.7.9-tetrahydropyrazolo 5,l-b1quinazolin-8( ' 4H)-one 1,3-Cyclohexanedione, 3-chloro-4-fluorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- 'H NMR (DMSO-d 6 ) ⁇ 10.54 (s, IH), 7.24-7.33 (m, 3H), 7.04-7.10 (m, IH), 6.19 (s, IH),
- Example 23 9-[4-(trifluoromethyl)phenyl]-5.6,7,9-tetrahvdropyrazolo[ " 5.1-blquinazolin-8( ' 4H -one 1,3-Cyclohexanedione, 4-trifluoromethylbenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 24 9-(4-cvanophenyl)-5,6.7.9-tetrahydropyrazolor5,l-blquinazolin-8(4H -one 1,3-Cyclohexanedione, 4-cyanobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 29 9-(3,4-dichloropheny ⁇ -7.7-dimethyl-5.6,7.9-tetrahvdropyrazolo[5 -blquinazolin-8(4H)-one 4,4-Dimethyl- 1,3-cyclohexanedione, 3,4-dichlorobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 34 9-(3-cyanophenyl ' )-7.7-dimethyl-5.6.7,9-tetrahvdropyrazolof5.1-b quinazolin-8(4H)-one 4,4-Dimethyl- 1,3-cyclohexanedione, 3-cyanobenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 40 9-(3-bromo-5-chloro-2-hvdroxyphenyl)-7.7-dimethyl-5,6.7.9-tetrahvdropyrazolor5.1- b]q uinazolin- 8 ( " 4H)-one 4,4-Dimethyl- 1 ,3 -cyclohexanedione, 3-bromo-5-chloro-2-hydroxybenzaldehyde and 3-aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 42 7.7-dimethyl-9-(3,4.5-trifluorophenv ⁇ -5.6.7.9-tetrahvdropyrazolor5,l-b1quinazolin-8(4H - one 4,4-Dimethyl- 1,3-cyclohexanedione, 3,4,5-trifluorobenzaldehyde and 3- aminopyrazole were processed as described in General Procedure A to provide the title compound.
- Example 48 The product from Example 48 and 3-chlorophenylboronic acid were processed as described in Example 43 to provide the title compound.
- Example 48 The product from Example 48 and 2-tributylstannylthiophene were processed as described in Example 51 to provide the title compound as light yellow solid.
- ⁇ NMR (DMSO-d 6 ) ⁇ 1.95 (m, 2H), 2.27 (m, 2H), 2.75 (m, 2H), 6.22 (s, IH), 7.11 (d, IH), 7.14 (dd, IH), 7.22 (d, IH), 7.45 (s, IH), 7.48 (d, IH), 7.52 (s, IH), 7.53 (d, IH), 10.30 (s, IH); MS (ESI+) m/z 416 (M + H+); MS (ESI-) m/z 414 (M-H) " Anal. Calcd for C20H15C12N3OS: C, 57.70; H, 3.63; N, 10.09. Found: C, 57.53; H, 3.46; N, 9.76.
- Example 48 3-bromo-9-(3,4-dichlorophenyl)-5,6.7.9-tetrahvdropyrazolo[5 -b "
- the product from Example 6 (0.52 g, 1.56 mmol) in dichloromethane was treated with N-bromosuccinimide (0.28 mg, 1.56 mmol) and allowed to stir at ambient temperature overnight. The mixture was filtered and the filter cake washed with CH C1 2 to provide the title compound (0.54 g) as a solid.
- Example 49 3-bromo-9-(3.4-dichlorophenv ⁇ -5.6.7.9-tetrahvdropyrazolo[5.1-blquinazolin-8(4H)-one
- the product from Example 48 was subjected to chiral column chromatography
- Example 48 The product from Example 48 was subjected to chiral column chromatography (Whelko column, 2.11 cm x 25 cm, eluting with 80:20 hexane:(CH 3 OH:CH 2 Cl 2 2:1)) to provide two enantiomers.
- Example 49 The product from Example 49 (0.2 g, 0.5 mmol) in DMF (4 mL) was treated with tetrakis(triphenylphosphine)palladium(0) (0.1 1 g) and 2-tributylstannylthiophene (0.41 g, 1.1 mmol). The reaction mixture was heated at 110 °C for 20 hours. After cooling to ambient temperature, the mixture was filtered through Celite and the filtrate diluted with ethylacetate. The diluted filtrate was washed with brine solution, dried over MgSO 4 and concentrated under reduced pressure.
- Example 50 9-( " 3,4-dichlorophenyl)-3-(2-thienyl)-5,6,7.9-tetrahvdropyrazolo
- the product from Example 50 was processed as described in Example 51 to provide the title compound as a light yellow solid.
- the mixture was then centrifuged at 1300 x g for 5 minutes, and the pellet resuspended in Dulbecco's PBS (GIBCO, Gaithersburg, MD) and recentrifuged to remove residual enzyme.
- the cell pellet was resuspended in 5 mL growth media (composition: Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units/mL penicillin, 100 units/mL streptomycin and 0.25 mg/mL amphotericin B) and further dissociated by pipetting the suspension through a flame-polished Pasteur pipette and passing it through a polypropylene mesh membrane (Spectrum, Houston, TX).
- the cell density was adjusted to 100,000 cells/mL by resuspension in growth media.
- Cells were plated in clear- bottomed black 96-well plates (Packard) for membrane potential studies at a density of 20,000 cells/well and maintained in a cell incubator with 90% air: 10% CO 2 until confluent.
- Cells were confirmed to be of smooth muscle type by cytoskeletal staining using a monoclonal mouse anti human- ⁇ -smooth muscle actin (Biomeda, Foster City, CA).
- DiBAC(4) 3 is an anionic potentiometric probe which partitions between cells and extracellular solution in a membrane potential-dependent manner. With increasing membrane potential (for example, K + depolarization), the probe further partitions into the cell; this is measured as an increase in fluorescence due to dye interaction with intracellular lipids and proteins.
- Confluent guinea-pig urinary bladder cells cultured in black clear-bottomed 96-well plates were rinsed twice with 200 mL assay buffer (composition, mM: HEPES, 20; NaCl, 120; KCl, 2; CaCl 2 , 2; MgCl 2 , 1; glucose, 5; pH 7.4 at 25 °C) containing 5 ⁇ M DiBAC(4) 3 and incubated with 180 mL of the buffer in a cell incubator for 30 minutes at 37 °C to ensure dye distribution across the membrane.
- the reference or test compounds, prepared at 10 times the concentration in the assay buffer were added directly to the wells. Changes in fluorescence were monitored for an additional 25 minutes.
- Hype ⁇ olarization responses were corrected for any background noise and were normalized to the response observed with 10 ⁇ M of the reference compound PI 075, N"-cyano-N-(tert-pentyl)-N'-(3-pyridinyl)guanidine, which was assigned as 100%.
- PI 075 is a potent opener of smooth muscle K ATP channels (Quast et al., Mol. Pharmacol., v. 43 pp. 474- 481 (1993)) and was prepared using the procedures described in (Manley, J. Med. Chem. (1992) 35, 2327-2340), hereby inco ⁇ orated by reference.
- Landrace pig bladders were obtained from female Landrace pigs of 9-30 kg. Landrace pigs were euthanized with an intraperitoneal injection of pentobarbital solution, Somlethal® , J.A: Webster Inc., Sterling MA. The entire bladder was removed and immediately placed into Krebs Ringer bicarbonate solution (composition, mM: NaCl, 120; NaHCO 3 , 20; dextrose, 11; KCl, 4.7; CaCl 2 , 2.5; MgSO 4 , 1.5; KH 2 PO 4 , 1.2; K 2 EDTA, 0.01, equilibrated with 5% CO 2 /95% O 2 pH 7.4 at 37 °C).
- composition, mM NaCl, 120; NaHCO 3 , 20; dextrose, 11; KCl, 4.7; CaCl 2 , 2.5; MgSO 4 , 1.5; KH 2 PO 4 , 1.2; K 2 EDTA, 0.01, equilibrated with
- Propranolol (0.004 mM) was included in all of the assays to block ⁇ -adrenoceptors. The trigonal and dome portions were discarded. Strips 3-5 mm wide and 20 mm long were prepared from the remaining tissue cut in a circular fashion. The mucosal layer was removed. One end was fixed to a stationary glass rod and the other to a Grass FT03 transducer at a basal preload of 1.0 gram. Two parallel platinum electrodes were included in the stationary glass rod to provide field stimulation of 0.05 Hz, 0.5 milli-seconds at 20 volts. This low frequency stimulation produced a stable twitch response of 100-500 centigrams.
- Tissues were allowed to equilibrate for at least 60 minutes and primed with 80 mM KCl.
- a control concentration response curve (cumulative) was generated for each tissue using the potassium channel opener PI 075 as the control agonist.
- PI 075 completely eliminated the stimulated twitch in a dose dependent fashion over a concentration range of 10 " 9 to 10 '5 M dissolved in DMSO using 1/2 log increments.
- a concentration response curve (cumulative) was generated for the test agonist in the same fashion as that used for the control agonist PI 075.
- the maximal efficacy of each compounds (expressed as % relative to PI 075) is reported.
- the compounds of this invention reduce stimulated contractions of the bladder and therefore may have utility in the treatment of diseases prevented by or ameliorated with potassium channel openers.
- Stereoisomers of the present invention may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom.
- R and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30.
- the stereochemistry at the point of attachment of R 1 may independently be either (R) or (S), unless specifically noted otherwise.
- the present invention contemplates various stereoisomers and mixtures thereof and are specifically included within the scope of this invention.
- Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
- Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns.
- pharmaceutically acceptable carrier means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
- materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols; such a propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen
- the present invention provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers.
- the pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration. Further included within the scope of the present invention are pharmaceutical compositions comprising one or more of the compounds of formula (I)-(IV) prepared and formulated in combination with one or more non-toxic pharmaceutically acceptable compositions.
- the pharmaceutical compositions can be formulated for oral administration in solid or liquid form, for parenteral injection or for rectal administration.
- compositions of this invention can be administered to humans and other mammals orally, rectally, parenterally , intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments or drops), bucally or as an oral or nasal spray.
- parenterally refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous, intraarticular injection and infusion.
- Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- aqueous and nonaqueous carriers, diluents, solvents or vehicles examples include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- a coating such as lecithin
- surfactants such as surfactants.
- These compositions may also contain adjuvants such as preservative agents, wetting agents, emulsifying agents, and dispersing agents.
- the abso ⁇ tion of the drug in order to prolong the effect of a drug, it is often desirable to slow the abso ⁇ tion of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amo ⁇ hous material with poor water solubility. The rate of abso ⁇ tion of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed abso ⁇ tion of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
- Suspensions in addition to the active compounds, may contain suspending agents, as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, tragacanth, and mixtures thereof.
- the compounds of the present invention can be inco ⁇ orated into slow-release or targeted-delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter or by inco ⁇ oration of sterilizing agents in the form of sterile solid compositions, which may be dissolved in sterile water or some other sterile injectable medium immediately before use.
- the active compounds can also be in micro-encapsulated form, if appropriate, with one or more excipients as noted above.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
- the active compound can be admixed with at least one inert diluent such as sucrose, lactose, or starch.
- Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
- the dosage forms may also comprise buffering agents.
- opacifying agents may optionally contain opacifying agents and can also be of such composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract in a delayed manner.
- embedding compositions which can be used include polymeric substances and waxes.
- Injectable depot forms are made by forming microencapsulated matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly (anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
- biodegradable polymers such as polylactide-polyglycolide.
- Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
- the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter or by inco ⁇ orating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
- sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic, parenterally acceptable diluent or solvent such as a solution in 1,3-butanediol.
- acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution.
- sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this pu ⁇ ose any bland fixed oil can be employed including synthetic mono- or diglycerides.
- fatty acids such as oleic acid are used in the preparation of injectables.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia; c) humectants such as glycerol; d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents such as paraffin; f) abso ⁇ tion accelerators such as quaternary ammonium compounds; g) wetting agents such as cetyl alcohol and glycerol monostea
- Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
- the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract in a delayed manner.
- Examples of embedding compositions which can be used include polymeric substances and waxes.
- compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
- the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
- inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and
- the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- the ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
- Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances.
- Sprays can additionally contain customary propellants such as chlorofiuorohydrocarbons.
- Liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes may be used.
- the present compositions in liposome form may contain, in addition to the compounds of the present invention, stabilizers, preservatives, excipients, and the like.
- the preferred lipids are the natural and synthetic phospholipids and phosphatidylcholines (lecithins) used separately or together.
- esters and amides refer to carboxylate salts, amino acid addition salts, zwitterions, esters and amides of compounds of formula (I)-(IV) which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, are commensurate with a reasonable benefit/risk ratio, and are effective for their intended use.
- the compounds of the present invention can be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids.
- pharmaceutically acceptable salt is meant those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
- Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 et seq.
- the salts can be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable organic acid.
- the basic nitrogen-containing groups can be quatemized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
- lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
- dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates
- long chain halides such as decyl
- acids which can be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid.
- Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
- a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
- Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like.
- Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.
- Preferred salts of the compounds of the invention include phosphate, tris and acetate.
- esters of compounds of the present invention refers to esters of compounds of the present invention which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof.
- examples of pharmaceutically acceptable, non-toxic esters of the present invention include C ⁇ -to-C 6 alkyl esters and C 5 -to-C 7 cycloalkyl esters, although C ⁇ -to-C 4 alkyl esters are preferred.
- Esters of the compounds of formula (I)-(IV) may be prepared according to conventional methods.
- 9-(3,4-dichlorophenyl)-3-(4-carboxyphenyl)-5,6,7,9-tetrahydropyrazolo[5,l- b]quinazolin-8(4H)-one can be treated with an acid, such as HCl, in an alcoholic solvent, such as methanol, to provide the ester 9-(3,4-dichlorophenyl)-3-(4-methoxycarbonylphenyl)- 5,6,7,9-tetrahydropyrazolo[5, 1 -b]quinazolin-8(4H)-one.
- an acid such as HCl
- an alcoholic solvent such as methanol
- pharmaceutically acceptable amide refers to non-toxic amides of the present invention derived from ammonia, primary C ⁇ -to-C 6 alkyl amines and secondary C ⁇ -to-C 6 dialkyl amines. In the case of secondary amines, the amine may also be in the form of a 5- or 6-membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C ⁇ -to-C 3 alkyl primary amides and C ⁇ -to-C 2 dialkyl secondary amides are preferred. Amides of the compounds of formula (I)-(IV) may be prepared according to conventional methods.
- 9-(3,4-dichlorophenyl)-3-(4-carboxyphenyl)-5,6,7,9- tetrahydropyrazolo[5,l-b]quinazolin-8(4H)-one can be treated with a chloroformate, such as isobutylchloroformate, in an organic solvent, such as tetrahydrofuran or methylene chloride at a temperature of about 0 °C to ambient temperature, to provide an intermediate anhydride which can then be treated with an amine, such as dimethylamine, to provide 9-(3,4- dichlorophenyl)-3 -(4-dimethylaminocarbonylpheny l)-5 ,6,7,9-tetrahydropyrazolo [5,1- b]quinazolin-8(4H)-one.
- amides of the present invention include amino acid and peptide derivatives of the compounds of formula (I), as well.
- prodrug or "prodrug,”as used herein, represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use.
- Prodrugs of the present invention may be rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood.
- a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, V. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press (1987), hereby inco ⁇ orated by reference.
- Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants.
- the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers or propellants which can be required.
- Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
- Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention can be varied so as to obtain an amount of the active compound(s) which is effective to achieve the desired therapeutic response for a particular patient, compositions and mode of administration.
- the selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the present invention contemplates pharmaceutically active compounds either chemically synthesized or formed by in vivo biotransformation to compounds of formula (I- (IV).
- the compounds of the invention including but not limited to those specified in the examples, possess potassium channel opening activity in mammals (especially humans).
- potassium channel openers the compounds of the present invention may be useful for the treatment and prevention of diseases such as asthma, epilepsy, male sexual dysfunction, female sexual dysfunction, pain, bladder overactivity, stroke, diseases associated with decreased skeletal blood flow such as Raynaud's phenomenon and intermittent claudication, eating disorders, functional bowel disorders, neurodegeneration, benign prostatic hype ⁇ lasia (BPH), dysmenorrhea, premature labor, alopecia, cardioprotection, coronary artery disease, angina and ischemia.
- diseases such as asthma, epilepsy, male sexual dysfunction, female sexual dysfunction, pain, bladder overactivity, stroke, diseases associated with decreased skeletal blood flow such as Raynaud's phenomenon and intermittent claudication, eating disorders, functional bowel disorders, neurodegeneration,
- the ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat benign prostatic hype ⁇ lasia (BPH) may be demonstrated by (Pandita, The J. of Urology (1999) 162, 943; Andersson; Prostate (1997) 30: 202-215).
- the ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat premature labor and dysmenorrhoea may be demonstrated by (Sanborn, Semin. Perinatol. (1995) 19, 31-40; Morrison, Am. J. Obstet. Gynecol. (1993) 169(5), 1277-85; Kostrzewska, Acta Obstet. Gynecol. Scand. (1996) 75(10), 886-91; Lawson, Pharmacol. Ther., (1996) 70, 39-63).
- the ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat epilepsy may be demonstrated by (Lawson, Pharmacol. Ther., (1996) 70, 39-63; Gopalakrishnan, Drug Development Research, (1993) 28, 95-127; Gehlert, Prog. Neuro-Psychopharmacol & Biol. Psychiat., (1994) 18, 1093-1102).
- the ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat neurodegenerative conditions and diseases such as cerebral ischemia, stroke, Alzheimer's disease and Parkinson's disease may be demonstrated by (Lawson, Pharmacol.
- the ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat myocardial injury during ischemia and reperfusion may be demonstrated by (Garlid, Circ Res (1997) 81(6), 1072-82; Lawson, Pharmacol. Ther., (1996) 70, 39-63; Grover, J. Mol. Cell Cardiol. (2000) 32, 677).
- the ability of the compounds of the present invention, including but not limited to those specified in the examples, to treat coronary artery disease may be demonstrated by (Lawson, Pharmacol. Ther., (1996) 70, 39-63, Gopalakrishnan, Drug Development Research, (1993) 28, 95-127).
- Aqueous liquid compositions of the present invention are particularly useful for the treatment and prevention of asthma, epilepsy, hypertension, Raynaud's syndrome, male sexual dysfunction, female sexual dysfunction, migraine, pain, eating disorders, urinary incontinence, functional bowel disorders, neurodegeneration and stroke.
- a therapeutically effective amount of one of the compounds of the present invention can be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester, amide or prodrug form.
- the compound can be administered as a pharmaceutical composition containing the compound of interest in combination with one or more pharmaceutically acceptable excipients.
- therapeutically effective amount means a sufficient amount of the compound to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgement.
- the specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
- the total daily dose of the compounds of this invention administered to a human or lower animal may range from about 0.003 to about 10 mg/kg/day.
- more preferable doses can be in the range of from about 0.01 to about 5 mg/kg/day.
- the effective daily dose can be divided into multiple doses for pu ⁇ oses of administration; consequently, single dose compositions may contain such amounts or submultiples thereof to make up the daily dose.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA02005016A MXPA02005016A (en) | 1999-11-19 | 2000-11-17 | Tricyclic dihydropyrimidine potassium channel openers. |
JP2001538911A JP2003529552A (en) | 1999-11-19 | 2000-11-17 | Tricyclic dihydropyrimidine potassium channel opener |
EP00980801A EP1242422A1 (en) | 1999-11-19 | 2000-11-17 | Tricyclic dihydropyrimidine potassium channel openers |
CA002391291A CA2391291A1 (en) | 1999-11-19 | 2000-11-17 | Tricyclic dihydropyrimidine potassium channel openers |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/443,212 | 1999-11-19 | ||
US09/443,212 US6274587B1 (en) | 1999-11-19 | 1999-11-19 | Tricyclic dihydropyrimidine potassium channel openers |
US09/709,923 US6538000B1 (en) | 1999-11-19 | 2000-11-10 | Tricyclic dihydropyrimidine potassium channel openers |
US09/709,923 | 2000-11-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001036422A1 true WO2001036422A1 (en) | 2001-05-25 |
Family
ID=27033456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/032333 WO2001036422A1 (en) | 1999-11-19 | 2000-11-17 | Tricyclic dihydropyrimidine potassium channel openers |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1242422A1 (en) |
JP (1) | JP2003529552A (en) |
CA (1) | CA2391291A1 (en) |
MX (1) | MXPA02005016A (en) |
WO (1) | WO2001036422A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
WO2010133794A1 (en) | 2009-05-18 | 2010-11-25 | Sanofi-Aventis | Anticancer compound and pharmaceutical composition containing the same |
WO2011121096A1 (en) * | 2010-03-31 | 2011-10-06 | Dkfz Deutsches Krebsforschungszentrum | PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS |
US8163768B2 (en) | 2005-07-20 | 2012-04-24 | Aventis Pharma S.A.. | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61227584A (en) * | 1985-03-15 | 1986-10-09 | Yoshitomi Pharmaceut Ind Ltd | Polyaza heterocyclic ring derivative |
EP0217142A2 (en) * | 1985-09-30 | 1987-04-08 | Yoshitomi Pharmaceutical Industries, Ltd. | A polyazaheterocyclic compound |
JPS6360985A (en) * | 1986-08-08 | 1988-03-17 | Yoshitomi Pharmaceut Ind Ltd | 4,7-dihydropyrazolo(1,5-a)pyrimidine derivative |
WO1989006535A1 (en) * | 1988-01-19 | 1989-07-27 | E.R. Squibb & Sons, Inc. | 2-OXO-1-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXYLIC ACID ESTERS |
US4918074A (en) * | 1984-03-12 | 1990-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Polyazaheterocycle compounds |
US5214047A (en) * | 1987-09-12 | 1993-05-25 | Basf Aktiengesellschaft | Tetracyclic quinazoline derivatives, effective as antiarrythmic agents |
-
2000
- 2000-11-17 JP JP2001538911A patent/JP2003529552A/en not_active Withdrawn
- 2000-11-17 CA CA002391291A patent/CA2391291A1/en not_active Abandoned
- 2000-11-17 MX MXPA02005016A patent/MXPA02005016A/en unknown
- 2000-11-17 EP EP00980801A patent/EP1242422A1/en not_active Withdrawn
- 2000-11-17 WO PCT/US2000/032333 patent/WO2001036422A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4918074A (en) * | 1984-03-12 | 1990-04-17 | Yoshitomi Pharmaceutical Industries, Ltd. | Polyazaheterocycle compounds |
JPS61227584A (en) * | 1985-03-15 | 1986-10-09 | Yoshitomi Pharmaceut Ind Ltd | Polyaza heterocyclic ring derivative |
EP0217142A2 (en) * | 1985-09-30 | 1987-04-08 | Yoshitomi Pharmaceutical Industries, Ltd. | A polyazaheterocyclic compound |
JPS6360985A (en) * | 1986-08-08 | 1988-03-17 | Yoshitomi Pharmaceut Ind Ltd | 4,7-dihydropyrazolo(1,5-a)pyrimidine derivative |
US5214047A (en) * | 1987-09-12 | 1993-05-25 | Basf Aktiengesellschaft | Tetracyclic quinazoline derivatives, effective as antiarrythmic agents |
WO1989006535A1 (en) * | 1988-01-19 | 1989-07-27 | E.R. Squibb & Sons, Inc. | 2-OXO-1-SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE-6-CARBOXYLIC ACID ESTERS |
Non-Patent Citations (2)
Title |
---|
PATENT ABSTRACTS OF JAPAN vol. 011, no. 069 3 March 1987 (1987-03-03) * |
PATENT ABSTRACTS OF JAPAN vol. 012, no. 283 3 August 1988 (1988-08-03) * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7772232B2 (en) | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
US8357704B2 (en) | 2004-04-15 | 2013-01-22 | Bristol-Myers Squibb Company | Fused heterocyclic compounds as inhibitors of potassium channel function |
US8163768B2 (en) | 2005-07-20 | 2012-04-24 | Aventis Pharma S.A.. | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them |
WO2010133794A1 (en) | 2009-05-18 | 2010-11-25 | Sanofi-Aventis | Anticancer compound and pharmaceutical composition containing the same |
WO2011121096A1 (en) * | 2010-03-31 | 2011-10-06 | Dkfz Deutsches Krebsforschungszentrum | PYRAZOL[1,5-a]PYRIMIDINE DERIVATIVES AS WNT PATHWAY ANTAGONISTS |
Also Published As
Publication number | Publication date |
---|---|
EP1242422A1 (en) | 2002-09-25 |
CA2391291A1 (en) | 2001-05-25 |
JP2003529552A (en) | 2003-10-07 |
MXPA02005016A (en) | 2003-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6780872B2 (en) | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | |
AU764163B2 (en) | Pyrano, piperidino, and thiopyrano compounds and methods of use | |
WO2001036422A1 (en) | Tricyclic dihydropyrimidine potassium channel openers | |
US6518279B2 (en) | Cyclopentanone dihydropyridine compounds useful as potassium channel openers | |
JP2004505081A (en) | Dihydronaphthyridine potassium channel opener | |
US6538000B1 (en) | Tricyclic dihydropyrimidine potassium channel openers | |
US20020099070A1 (en) | Dihydronaphthyridine potassium channel openers | |
US6274587B1 (en) | Tricyclic dihydropyrimidine potassium channel openers | |
EP1259510B1 (en) | Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers | |
EP1278747B1 (en) | Pyrano, piperidino, and thiopyrano compounds and methods of use | |
JP2002528452A (en) | Dihydropyridine compounds and methods of use | |
JP2004509840A (en) | Dihydropyridine compounds and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP MX |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2391291 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2001 538911 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2002/005016 Country of ref document: MX Ref document number: 2000980801 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000980801 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000980801 Country of ref document: EP |